BrenipatideLY3537031
A long-acting dual GIP/GLP-1 agonist aimed at the brain's reward circuitry rather than the scale.
The same two-receptor sentence tirzepatide speaks, pointed at the brain instead of the scale — a gut signal being read for what it might say about craving.
Identity
- Class
- GIP/GLP-1 dual agonist (acylated peptide)
- Source
- Synthetic; engineered long-acting dual agonist (Eli Lilly)
- Receptor
- GIP + GLP-1 receptors
Key properties
Evidence floorClinicalREF1CLIN1Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.
Mechanism
Brenipatide engages the same two receptors as tirzepatide — GIP and GLP-1 — from a single acylated peptide, but is engineered for a far longer duration; the dosing interval has not been disclosed. Its development is unusual for the class: the lead RENEW program studies neuropsychiatric and addiction indications, betting that incretin co-agonism modulates the dopamine reward pathways behind craving and mood, not only appetite. It is investigational.
In depth
For a decade the incretin story was a metabolic one: hold blood sugar, quiet appetite, lower weight. Brenipatide shares the machinery — two receptors, GIP and GLP-1, read by one engineered peptide, armoured to outlast the enzymes that clear the native hormones — yet it is pointed somewhere else. Lilly is leading its development not with obesity but with alcohol use disorder and major depression — the two Phase 3 arms of the RENEW program — with bipolar disorder, schizophrenia, opioid use disorder and smoking relapse following at Phase 2, chasing the growing evidence that these gut signals also speak to the brain's reward system.
The design choices follow the ambition. A drug meant to blunt craving over months, not meals, benefits from the longest possible reach; brenipatide is built for an extended interval Lilly has not yet disclosed, and the 56-week Phase 3 protocols leave room for it to be among the most durable peptides in the class. Whether co-agonism that reshapes metabolism can also quiet the dopamine loops behind addiction and mood is the open question the RENEW trials exist to settle — a bet that the incretin sentence, once written for the pancreas, can be read by the brain.
Reference notes
- A dual GIP/GLP-1 agonist — the same receptor pair as tirzepatide — engineered for a far longer dosing interval than the weekly incretins.
- Phase 3 first in psychiatry: the RENEW program runs two 1,100-participant trials in alcohol use disorder (RENEW-ALC) and two 1,000-participant trials of adjunctive treatment in major depressive disorder (RENEW-MDD), each 56 weeks, reading out from 2028.
- Phase 2 trials span bipolar disorder, schizophrenia, opioid use disorder, smoking relapse, irritable bowel syndrome, asthma, and COPD; obesity, the class's home ground, is still at Phase 1.
- The wager is that GIP/GLP-1 signalling reaches the brain's dopamine reward circuitry, extending the class from metabolism into addiction and mood.
- Developed by Eli Lilly and investigational — not approved for any use.
Regulatory status
United States · reviewed September 2026- Basis
- Phase 3 RENEW program (Eli Lilly) in alcohol use disorder and major depressive disorder; Phase 2 across psychiatric, addiction, gut and airway indications. No approval.
Status describes the molecule as a drug substance under US law and is an editorial reading of the public record — approvals, trial registrations, and the FDA 503A bulk-substances list. It is not legal advice and it changes; the review date above is the last time the table was checked. Other jurisdictions are noted only where they differ materially.
Common questions
- What is Brenipatide (LY3537031)?
- A long-acting dual GIP/GLP-1 agonist aimed at the brain's reward circuitry rather than the scale. Structurally it is GIP/GLP-1 dual agonist (acylated peptide).
- How does LY3537031 work?
- Brenipatide engages the same two receptors as tirzepatide — GIP and GLP-1 — from a single acylated peptide, but is engineered for a far longer duration; the dosing interval has not been disclosed. Its development is unusual for the class: the lead RENEW program studies neuropsychiatric and addiction indications, betting that incretin co-agonism modulates the dopamine reward pathways behind craving and mood, not only appetite. It is investigational.
- How strong is the evidence for LY3537031?
- PeptideHormone grades LY3537031 at the "Investigational" evidence tier — it is under active human investigation — promising, but not yet settled. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
- What is the half-life of LY3537031?
- The reported circulating half-life of LY3537031 is engineered for an extended dosing interval (not yet disclosed).
- Is LY3537031 FDA-approved?
- No — as of September 2026, LY3537031 is in registered human trials but not approved for any indication. Phase 3 RENEW program (Eli Lilly) in alcohol use disorder and major depressive disorder; Phase 2 across psychiatric, addiction, gut and airway indications. No approval. Status is US-centric and can change; check the FDA record for the current position.
In the literature
Live registry counts · retrieved- Ph 16
- Ph 28
- Ph 34
- Ph 40
Searched as Brenipatide, LY3537031. Counts are search hits from the primary registries, not a curated set and not a grade – a measure of how much work exists on LY3537031, not how it turned out.
External references
LY3537031 in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.